BioNTech SE(US:BNTX) 美股IPO·2026-03-10 23:55Core Insights - The company reported a fourth-quarter adjusted loss that was below analyst expectations, with a diluted adjusted loss per share of €0.33 compared to a profit of €1.79 per share a year earlier [2] - The quarterly revenue for the period ending December 31 was €907.4 million, down from €1.19 billion a year ago, while analysts had expected revenue of €768.3 million [2] - For the full year 2026, the company projected revenue between €2 billion and €2.3 billion, which is lower than the analyst expectation of €2.75 billion [2] Company Developments - The founder of BioNTech SE is leaving the company to establish a new biotechnology firm focused on messenger RNA (mRNA) technology, which is the core technology behind its successful COVID-19 vaccine [3]